On the other hand, SPS2 targets the Se dependency of cancers such as breast cancer, lymphoma, and melanoma by disrupting selenoprotein synthesis and inducing toxic selenide accumulation, selectively eliminating cancer cells without harming normal tissues [71]. The gene discussed is SEPHS2; the disease is melanoma.